Olpasiran cuts lipoprotein(a) by 97% or more at mid and high doses in the Phase 2 OCEAN(a)-DOSE trial

Amgen/Olpasiran

In 281 patients with heart disease and high Lp(a), olpasiran lowered Lp(a) in a dose-dependent way, with placebo-adjusted reductions of about 97% to 101% at the three higher doses after 36 weeks. Side effects were similar to placebo apart from mild injection-site reactions. The results, presented at AHA 2022 and published in NEJM, set up Phase 3.

• Placebo-adjusted change at week 36: -70.5% (10 mg), -97.4% (75 mg), -101.1% (225 mg every 12 weeks), -100.5% (225 mg every 24 weeks).
• Median baseline Lp(a) was 260 nmol/L; median LDL cholesterol 67.5 mg/dL.
• Adverse events were similar to placebo; injection-site reactions were more common but mild.